Daily oral treatment with memantine did not slow disease progression nor did it reduce biomarker changes among people with amyotrophic lateral sclerosis (ALS) enrolled in a Phase 2b trial. Approved under the brand name Namenda to treat cognitive problems in people with Alzheimer’s disease, memantine has also…
AAN 2023: Memantine fails to slow disease progression in Phase 2b trial
Sponsored Content
Having ALS Doesn’t Stop Me from Living My Best Life Every Day
For 30 years in the medical field, Debra saw others find the courage to move forward with tough diseases. When she heard her ALS diagnosis, she knew what to do. Learn how Debra decided to get up every day and keep going.
Recognized each May, ALS Awareness Month provides an opportunity for people living with amyotrophic lateral sclerosis and their families — as well as healthcare professionals, researchers, experts, and advocates — to increase awareness and education in the community at large, and to raise funds, all in the hope of…
Making and keeping friends did not come naturally to me in childhood. I was shy, and my introversion and love of books often kept me curled up on the couch reading while other neighborhood kids biked and played tag. I craved the interactions I noticed other kids having,…
When my two teenagers came home from school, I had them sit down to listen to the first five minutes of a recent “Freakonomics Radio” podcast episode, “Swearing Is More Important Than You Think.” The host, Stephen Dubner, is struck that there seems to be more swearing now than…
It’s been nearly three years since the HEALEY platform clinical trial started and, so far, two promising experimental treatments for amyotrophic lateral sclerosis (ALS) have been identified. Both potential medications — CNM-Au8 and pridopidine — are headed toward Phase 3 clinical testing, while testing has been ruled…
Treatment with the investigational therapy DNL343 was generally well-tolerated among people with amyotrophic lateral sclerosis (ALS) in an early clinical trial, and biomarker data from the trial suggest that the therapy is working as intended. Results were presented at the annual meeting of the American Academy of Neurology (AAN),…
The U.S. Food and Drug Administration (FDA) has granted conditional approval to Biogen’s tofersen, now named Qalsody, for the treatment of amyotrophic lateral sclerosis (ALS) associated with mutations in the SOD1 gene. The decision, which marks the first conditional approval for ALS in the country, comes about eight…
Imagine this: A 71-year-old ALS patient riding a mobility scooter visits her local furniture store. I mean, what can go wrong? Well, a whole heck of a lot can go wrong, at least according to all the worst-case scenarios that flooded my mind. From the comical to the complete…
A new technology powered by artificial intelligence (AI) may one day help doctors diagnose people in the early stages of amyotrophic lateral sclerosis (ALS), according to data from a clinical trial. Developed by Pison, the technology was able to detect involuntary muscle twitches, or fasciculations, and changes in…
Recent Posts
- ALS Network, ALS United calling for ‘bold’ research proposals for funding
- Study finds common medications that could be repurposed to treat ALS
- New eye imaging approach may help distinguish ALS from Alzheimer’s
- After 15 years as an ALS caregiver, I’m still learning from others
- Early PrimeC use slows ALS progression, reduces complication risk